Distribution of Four Polymorphisms in the Tumour Necrosis Factor (TNF) Genes in Patients with Inflammatory Bowel Disease (IBD)

Overview

Journal Clin Exp Immunol

Publisher Oxford University Press

Specialty Allergy & Immunology

Date 1996 Mar 1

PMID 8608636

Citations 36

Authors

G Bouma

B Xia

J B Crusius

G Bioque

I Koutroubakis

B M von Blomberg

S G Meuwissen

A S Pena

Affiliations

Soon will be listed here.

Abstract

In 153 patients with IBD, 64 with Crohn's disease (CD), and 89 with ulcerative colitis (UC), as well as in 54 healthy controls (HC), the frequencies of four known di-allelic polymorphisms in the genes for TNF-alpha and lymphotoxin alpha (LTalpha) were investigated. In the Dutch population, the alleles of these four polymorphisms are present in only five combinations, called TNF haplotypes: TNF-C, -E, -H, -I, -P. Furthermore, the relation with the presence of perinuclear anti-neutrophil cytoplasmic autoantibodies (P-ANCA) was studied. A small, but statistically significant, association between the polymorphism at position -308 in the promoter region of the TNF-alpha gene and UC was found. The frequency of the uncommon TNF-alpha -308 allele 2 was found to be decreased in patients with UC compared with HC (allele frequency of allele 2 in UC patients 0-15 versus 0.25 in HC, P=0.044). No significant differences in distribution of the TNF haplotypes were found between IBD patients and HC, although there was a tendency towards a higher frequency of the TNF-C haplotype in UC patients compared with controls (haplotype frequency 22% versus 13%; P=0.19). No statistically significant differences in distribution of the TNF haplotypes were observed between P-ANCA-positive and P-ANCA-negative UC patients. The strength of the associations indicates that TNF genes are not markers for the predisposition to suffer from IBD. They may, however, be markers of subsets of patients with UC and CD.

Citing Articles

Genetic polymorphisms in tumour necrosis factor receptors () illustrate differential treatment response to TNFα inhibitors in patients with Crohn's disease.

Qasem A, Ramesh S, Naser S BMJ Open Gastroenterol. 2019; 6(1):e000246.

PMID: 30815272 PMC: 6361334. DOI: 10.1136/bmjgast-2018-000246.

The role of diet in the prevention and treatment of Inflammatory Bowel Diseases.

Reddavide R, Rotolo O, Caruso M, Stasi E, Notarnicola M, Miraglia C Acta Biomed. 2018; 89(9-S):60-75.

PMID: 30561397 PMC: 6502201. DOI: 10.23750/abm.v89i9-S.7952.

TNF-α and IL-1 β Cytokine Gene Polymorphism in Patients with Nasal Polyposis.

Ismi O, Ozcan C, Polat G, Kul S, Gorur K, Puturgeli T Turk Arch Otorhinolaryngol. 2018; 55(2):51-56.

PMID: 29392055 PMC: 5782942. DOI: 10.5152/tao.2017.2389.

Diet, Gut Microbiome and Epigenetics: Emerging Links with Inflammatory Bowel Diseases and Prospects for Management and Prevention.

Aleksandrova K, Romero-Mosquera B, Hernandez V Nutrients. 2017; 9(9).

PMID: 28867793 PMC: 5622722. DOI: 10.3390/nu9090962.

Tumor necrosis factor-α -G308A polymorphism is associated with liver pathological changes in hepatitis C virus patients.

Bader El Din N, Farouk S, El-Shenawy R, Ibrahim M, Dawood R, Elhady M World J Gastroenterol. 2016; 22(34):7767-77.

PMID: 27678360 PMC: 5016377. DOI: 10.3748/wjg.v22.i34.7767.

References

Ferencik S, Lindemann M, Horsthemke B, Grosse-Wilde H . A new restriction fragment length polymorphism of the human TNF-B gene detected by AspHI digest. Eur J Immunogenet. 1992; 19(6):425-30. DOI: 10.1111/j.1744-313x.1992.tb00086.x. View

Shanahan F, Duerr R, Rotter J, Yang H, Sutherland L, McElree C . Neutrophil autoantibodies in ulcerative colitis: familial aggregation and genetic heterogeneity. Gastroenterology. 1992; 103(2):456-61. DOI: 10.1016/0016-5085(92)90834-l. View

Wilson A, de Vries N, Pociot F, Di Giovine F, van der Putte L, Duff G . An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med. 1993; 177(2):557-60. PMC: 2190902. DOI: 10.1084/jem.177.2.557. View

Oudkerk Pool M, Ellerbroek P, Ridwan B, Goldschmeding R, von Blomberg B, Pena A . Serum antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease are mainly associated with ulcerative colitis. A correlation study between perinuclear antineutrophil cytoplasmic autoantibodies and clinical parameters, medical, and.... Gut. 1993; 34(1):46-50. PMC: 1374099. DOI: 10.1136/gut.34.1.46. View

Toyoda H, Wang S, Yang H, Redford A, Magalong D, Tyan D . Distinct associations of HLA class II genes with inflammatory bowel disease. Gastroenterology. 1993; 104(3):741-8. DOI: 10.1016/0016-5085(93)91009-7. View

Sugimura K, Asakura H, Mizuki N, Inoue M, Hibi T, Yagita A . Analysis of genes within the HLA region affecting susceptibility to ulcerative colitis. Hum Immunol. 1993; 36(2):112-8. DOI: 10.1016/0198-8859(93)90113-f. View

Wilson A, Di Giovine F, Blakemore A, Duff G . Single base polymorphism in the human tumour necrosis factor alpha (TNF alpha) gene detectable by NcoI restriction of PCR product. Hum Mol Genet. 1992; 1(5):353. DOI: 10.1093/hmg/1.5.353. View

Yang H, Rotter J, Toyoda H, Landers C, Tyran D, McElree C . Ulcerative colitis: a genetically heterogeneous disorder defined by genetic (HLA class II) and subclinical (antineutrophil cytoplasmic antibodies) markers. J Clin Invest. 1993; 92(2):1080-4. PMC: 294949. DOI: 10.1172/JCI116613. View

DAlfonso S, Richiardi P . A polymorphic variation in a putative regulation box of the TNFA promoter region. Immunogenetics. 1994; 39(2):150-4. DOI: 10.1007/BF00188619. View

10.

Satsangi J, Jewell D, Rosenberg W, Bell J . Genetics of inflammatory bowel disease. Gut. 1994; 35(5):696-700. PMC: 1374760. DOI: 10.1136/gut.35.5.696. View

11.

Masuda H, Nakamura Y, Tanaka T, Hayakawa S . Distinct relationship between HLA-DR genes and intractability of ulcerative colitis. Am J Gastroenterol. 1994; 89(11):1957-62. View

12.

Duerr R, Neigut D . Molecularly defined HLA-DR2 alleles in ulcerative colitis and an antineutrophil cytoplasmic antibody-positive subgroup. Gastroenterology. 1995; 108(2):423-7. DOI: 10.1016/0016-5085(95)90069-1. View

13.

Futami S, Aoyama N, Honsako Y, Tamura T, Morimoto S, Nakashima T . HLA-DRB1*1502 allele, subtype of DR15, is associated with susceptibility to ulcerative colitis and its progression. Dig Dis Sci. 1995; 40(4):814-8. DOI: 10.1007/BF02064985. View

14.

Bouma G, Oudkerk Pool M, Scharenberg J, Kolkman J, von Blomberg B, Scheper R . Differences in the intrinsic capacity of peripheral blood mononuclear cells to produce tumor necrosis factor alpha and beta in patients with inflammatory bowel disease and healthy controls. Scand J Gastroenterol. 1995; 30(11):1095-100. DOI: 10.3109/00365529509101613. View

15.

Freidel A, BETUEL H, Gebuhrer L, Farre A, Lambert J . Cellular and serological subtypes of HLA-DR2. Tissue Antigens. 1987; 29(3):129-40. DOI: 10.1111/j.1399-0039.1987.tb01565.x. View

16.

Wiik A . Delineation of a standard procedure for indirect immunofluorescence detection of ANCA. APMIS Suppl. 1989; 6:12-3. View

17.

Jacob C, Fronek Z, Lewis G, Koo M, Hansen J, McDevitt H . Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci U S A. 1990; 87(3):1233-7. PMC: 53445. DOI: 10.1073/pnas.87.3.1233. View

18.

Lennard-Jones J . Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989; 170:2-6; discussion 16-9. DOI: 10.3109/00365528909091339. View

19.

Saxon A, Shanahan F, Landers C, Ganz T, Targan S . A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol. 1990; 86(2):202-10. DOI: 10.1016/s0091-6749(05)80067-3. View

20.

Messer G, Spengler U, Jung M, Honold G, Blomer K, Pape G . Polymorphic structure of the tumor necrosis factor (TNF) locus: an NcoI polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production. J Exp Med. 1991; 173(1):209-19. PMC: 2118757. DOI: 10.1084/jem.173.1.209. View